MAGEC2 Antibody
Description
Characteristics of MAGEC2 Antibody
The MAGEC2 Antibody is available in two primary forms: polyclonal and monoclonal. Key specifications include:
Both antibodies are validated for human samples, with the polyclonal version optimized for tissue-based assays and the monoclonal version suited for biochemical techniques like immunoprecipitation.
Research Findings on MAGEC2 Antibody
The antibody has been instrumental in elucidating MAGEC2’s role in oncogenesis:
2.1. Prognostic Significance in Hepatocellular Carcinoma (HCC)
-
OS: High expression → median survival = 20.3 months (P = 0.0048).
-
RFS: High expression → median survival = 14.5 months (P = 0.036).
2.2. Mechanistic Insights
-
Tumor Growth Promotion: Knockdown of MAGEC2 via shRNA in HCC cell lines (e.g., MHCC97H) reduced xenograft tumor size by 60% compared to controls (P = 0.002) .
-
Epithelial-to-Mesenchymal Transition (EMT): MAGEC2 knockdown increased epithelial markers (E-cadherin) and decreased mesenchymal markers (N-cadherin, fibronectin), suggesting its role in promoting metastasis .
-
Protein Interactions: MAGEC2 interacts with TRIM28 (a ubiquitin ligase) and TAF9 (a transcription coactivator), stabilizing its expression and facilitating oncogenic signaling .
Clinical and Therapeutic Implications
-
Biomarker Potential: Elevated MAGEC2 expression has been linked to aggressive phenotypes in breast, lung, and melanoma cancers, making it a candidate for diagnostic panels .
-
Immunotherapy Target: As a CTA, MAGEC2 is under investigation for vaccine development and adoptive T-cell therapies. Early-phase trials (e.g., MAGE-C2 peptide vaccines) have shown safety and immune responses in cancer patients .
Limitations of Current Research
-
Heterogeneity in Expression: Regional and racial differences in MAGEC2 expression (higher in East Asian HCC cohorts) necessitate diverse patient sampling in trials .
-
Mechanistic Gaps: The exact signaling pathways downstream of MAGEC2 (e.g., Cyclin E regulation, apoptosis inhibition) remain understudied .
Product Specs
Target Background
MAGEC2 Antibody: Gene References and Functions
- MAGEC2 directly binds TAF9 via its CR domain, suggesting that MAGEC2 may be involved in TAF9 binding with DNA to regulate certain gene transcription. PMID: 29257297
- Our findings revealed a previously unrecognized regulation of STAT3 activation in tumor cells by cancer/testis antigen MAGEC2, providing a molecular mechanism for the oncogenic activity of MAGEC2 in cancer cells. PMID: 27775077
- High MAGE-C2 expression was found in 38.18% of triple-negative breast cancer tissues and in 9.09% of adjacent tissues. High MAGE-C2 expression in TNBC patients was closely associated with tumor node metastasis and shorter survival time. PMID: 27843173
- Our study provides a suitable cell model for exploring the biological functions of MAGEC2 in malignant cells and sheds light on the molecular pathway by which MAGEC2 promotes tumor development. PMID: 27636589
- The expressions of MAGE-C2 mRNA and MAGE-C2 protein were closely associated with the stage and metastasis of lung cancer. PMID: 26903162
- In gastrointestinal stromal tumors, 5/51 (10%) patients expressed MAGE-C2. High-grade GIST are more likely to express MAGE-C2. MAGE-C2 also significantly correlates with mitotic rate and tumor size. PMID: 24713551
- Our results indicate that MAGEC2 plays a role in breast cancer metastasis through inducing epithelial-mesenchymal transition. PMID: 24687377
- Overexpression of HCA587 resulted in a significant enhancement of LMP1-induced IL-6 production. These data indicate that HCA587 is a new negative regulator of BS69. PMID: 24866244
- MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair. PMID: 23096706
- Cytotoxic T cell clones directed against MAGE-C2 peptides recognize EB81-melanoma tumor cells treated with interferon (IFN)-gamma. PMID: 22925930
- MAGE-C2/CT10 expression in prostate cancer correlates with the degree of malignancy and indicates a higher risk for biochemical recurrence after radical prostatectomy. PMID: 21754986
- MAGEC2 is a sensitive and novel marker for seminoma. PMID: 21780320
- p43-57 is the first HCA587-derived major histocompatibility complex class II-restricted epitope to fulfill all prerequisites for use as a peptide vaccine in patients with HCA587-expressing tumors. PMID: 21595801
- HCA 587 may be a valuable target antigen for diagnosis and vaccination of hepatocellular carcinoma patients. PMID: 12920247
- Identified two antigens encoded by the MAGE-C2 gene, which are recognized by several melanoma-specific cytolytic T lymphocyte clones isolated from a melanoma patient. Both antigens are presented by HLA-A2. PMID: 14999777
- CT10 expression was more frequently found in squamous cell carcinoma than in adenocarcinoma. PMID: 15061963
- Due to the expression pattern of the MAGE-C2 gene, this new antigen is strictly tumor-specific. PMID: 17096150
- The MAGE-A3 and MAGE-C2 gene promoter regions are de-methylated in the presence of activated KIT but become methylated upon inhibition of KIT, consistent with the downregulation of mRNA and protein. PMID: 17495964
- MAGE-C2/CT-10 is expressed in hepatocellular carcinoma. PMID: 18942708
